Long-term therapy with tumor necrosis factor-alpha (TNF-α) inhibitors – a cornerstone in the treatment of severe immune-mediated inflammatory diseases – can induce paradoxical reactions (PR): the de novo onset or exacerbation of immune-mediated dermatoses that are pathogenetically related to the conditions for which the drug was prescribed. The pathogenesis of PR arises from a disruption of systemic immune homeostasis following blockade of TNF-α, a pleiotropic cytokine with diverse regulatory functions. This leads to cytokine imbalance, a shift in the dominant T-helper immune response, and hyperactivation of alternative pro-inflammatory pathways. Clinically, PR are highly heterogeneous, encompassing psoriasiform, eczematous, lichenoid, and granulomatous reactions, as well as paradoxical neutrophilic dermatoses – each characterized by distinct epidemiological and clinicomorphological features. The development of PR is determined by the interplay between pharmacological intervention and the patient’s individual genetic background. The study of PR is of considerable interest not only in the context of pharmacovigilance but also as a unique in vivo model for investigating human immune homeostasis, illustrating the high degree of compensatory capacity and nonlinearity inherent in cytokine networks.

Purpose of the review: to systematize current understanding of the pathogenesis of paradoxical reactions (PR) occurring during genetically engineered biological therapy with tumor necrosis factor-alpha (TNF-α) inhibitors.

Skin aging is a multi-level pathological process characterized by heterogeneity and a close interconnection of molecular and cellular disturbances. These include loss of proteostasis and epigenetic alterations, activation of specific pro-inflammatory cascades, mitochondrial dysfunction, and persistent disruption of intercellular communication, among others. The accumulation of such damages poses a significant methodological challenge for contemporary local geroprotection, necessitating a move beyond mono-therapeutic approaches. This review analyzes the pathogenetic foundations for developing combined strategies. The primary focus is on the synergistic potential of combining Intense Pulsed Light (IPL) with injectable cosmetology methods. Within this framework, the potential for targeted delivery of vitamins, peptides, amino acids, and trace elements in the form of mechano-chemical conjugates is evaluated for correcting deep metabolic deficits associated with aging. Based on a systematization of current data, a conceptual model is formulated that substantiates the need for personalized combined protocols. It is proposed that such a multimodal strategy, sequentially targeting various pathogenetic links – from neutralizing exogenous aggressors and mitigating chronic inflammation to directly restoring the extracellular matrix and cellular homeostasis – can not only effectively correct the visual manifestations of aging but also influence fundamental biological processes. Thus, a rational combination of IPL therapy and modern bioreparants is considered a promising avenue for achieving sustainable clinical results in correcting both chronological and photo-induced skin aging.

Psoriasis and psoriatic arthritis (PsA) are recognized as heterogeneous immune-mediated inflammatory disorders with a pronounced systemic component, whose development is driven by complex interactions between innate and adaptive immunity. The IL-23/Th17/IL-17 axis plays a central role in the pathogenesis of psoriatic disease; however, increasing attention is being directed toward non-axis mediators, including IL-6, IL-8, IL-22, IL-33, and IL-35, which reflect tissue specificity and immunological heterogeneity. The introduction of TNF-α and IL-17A inhibitors has significantly improved both cutaneous and articular outcomes; nevertheless, variability in clinical response and secondary loss of efficacy remain substantial challenges. Evidence from clinical and immunological studies demonstrates heterogeneity in the dynamics of circulating cytokines during biologic therapy and underscores the need for reliable predictive biomarkers of treatment response. A comprehensive assessment of cytokine profiles, together with accessible hematological markers of systemic inflammation- particularly the neutrophil-to-lymphocyte ratio (NLR) – may represent a promising approach for disease monitoring and the advancement of personalized therapeutic strategies.

Plasma-assisted skin regeneration (PSR) is a modern non-ablative hardware-assisted rejuvenation technology based on the controlled thermal action of ionized gas (plasma). This review systematizes the fundamental physical principles of the method, in particular, the key differences between the two main types of plasma used – nitrogen (N2) and helium (He), which determine the features of their mechanism of action. The unique histological changes induced by PSR are considered in detail – the formation of the zone of thermal damage (ZTD) and the zone of thermal modification (ZTM), which underlie the pathogenesis of subsequent re-epithelialization and neocollagenesis. Data on the dynamics of tissue regeneration and the main clinical effects are presented, including the «biological dressing» effect, improved skin texture, and lifting. Comparative data of PSR with an ablative CO2 laser are presented, and the clinical indications for each technology are determined. The article discusses the indications for the use of PSR, its safety profile, possible complications, and contraindications. It is concluded that PSR occupies an important place in the arsenal of aesthetic medicine as a method that provides a predictable rejuvenating effect with a relatively short recovery period and a high level of safety for various skin phototypes.

Understanding the pathogenetic relationship between psoriasis and obesity is crucial, as excess weight can reduce the effectiveness of medications, highlighting its clinical significance not only in the context of disease severity but also in relation to therapeutic outcomes, including with the use of genetically engineered biological therapies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs that act on incretin hormone pathways, normalizing metabolic disorders. Clinical trials have been published on the use of GLP-1 agonists in patients with psoriasis. In this context, studying the combined use of genetically engineered drugs and GLP-1 agonists in patients with psoriasis and associated metabolic syndrome is relevant.

Material and methods. Twelve patients with psoriasis and metabolic syndrome were observed. All patients were prescribed netakimab 120 mg and tirzepatide according to the package insert.

Results. The PASI index (PASI) scores were statistically significant (p<0.001) from pre-treatment to week 26, reaching PASI 90 and 100 in all patients, indicating a significant clinical response to therapy. In the study group, the median weight loss was 14 kg (95% CI: 12.00–15.00), with a minimum weight loss of 10 kg and a maximum of 15 kg. The average percentage weight loss was 13.02±1.23.

Conclusions. A comprehensive approach to treating patients with severe psoriasis and associated metabolic syndrome with significant excess body weight is the most appropriate strategy, as this category of patients is at risk of an insufficient response to genetically engineered drugs. This observational study demonstrated the high efficacy and safety of a genetically engineered IL-17A blocker (netakimab) and tirzepatide.

Rosacea is a chronic, genetically determined skin disease predominantly affecting the facial skin. It is characterized by vascular (erythema, telangiectasias) and inflammatory (papules, pustules) changes. Less commonly, the sebaceous glands are involved, leading to the formation of phyma. The development of effective and safe treatments for rosacea in patients with comorbid somatic pathologies, including metabolic syndrome, remains a pressing interdisciplinary challenge. Study objective. To evaluate the efficacy of combined use of systemic isotretinoin at a dose of 10 mg/day and BBL light technology (420–1400 nm) in patients with the erythematotelangiectatic subtype of rosacea associated with metabolic disorders, taking into account clinical symptoms and quality of life indicators based on immediate and long-term follow-up.

Methods. A single-center, open-label, prospective, randomized, comparative study included 39 patients with erythematotelangiectatic rosacea (ETR) with one or more metabolic syndrome components. Patients were divided into two groups. Group 1A (n=19) received broadband pulsed light (BBL) therapy, while Group 1B received combination therapy with isotretinoin (10 mg/day for 4 months) and BBL light technology. Skin lesion activity was assessed using the modified Dermatology Index of the Rosacea Symptom Scale (DIRSS). The impact of dermatosis on patients’ quality of life was assessed using the Dermatology Index of Quality of Life (DIQOL). Follow-up examinations were conducted before treatment, after completion of therapy, and at 6 and 12 months after completion of treatment.

Results. According to the DISHSR and DIQI indices, both broadband light monotherapy and the combination regimen containing isotretinoin demonstrated high efficacy in the short-term follow-up period. However, in the long-term follow-up period (6 and 12 months), a significant advantage of Group 1B was established for the studied indices.

Conclusion. The results of this study confirm the high efficacy of BBL phototherapy and the combination regimen containing systemic isotretinoin and BBL phototherapy in the treatment of erythematotelangiectatic rosacea in patients with metabolic disorders. However, the developed combination treatment regimen has a more pronounced preventive potential.

Background. Atopic dermatitis (AD) is a chronic inflammatory skin disease with a multifactorial pathogenesis and marked clinical heterogeneity. A comprehensive assessment combining demographic and clinical-history data, objective biomarkers, and atopic comorbidities expands the possibilities for personalized care.

Aim. To stratify patients with atopic dermatitis according to severity based on clinical and anamnestic data and filaggrin protein levels.

Materials and methods. In a single-centre prospective study, disease severity was determined using the Investigator’s Global Assessment (IGA) score, and filaggrin expression was determined using tape stripping followed by immunohistochemical analysis. Demographic characteristics, data on atopic comorbidities, and family history of atopy were also collected.

Results. Ninety patients were included; moderate and severe severity prevailed (36/90 and 34/90). Onset in childhood was more common in IGA 3/4 (30/34 in the severe group; 14/36 in the moderate group). Filaggrin levels differed between groups: median 0.171 [0.107; 0.254] in the severe group and 0.499 [0.339; 1.038] in the moderate group; in IGA 1–2, the values were higher (0.415 [0.372; 0.458] and 0.433 [0.191; 0.618]).

Conclusion. The phenotypic profile of patients with AD changes significantly as the disease worsens and is associated with age of onset, atopic comorbidities, and filaggrin barrier marker levels. Non-invasive assessment of filaggrin using tape stripping has demonstrated technological simplicity and clinical comparability with severity, allowing it to be considered as an additional monitoring tool in clinical practice.

Seborrheic dermatitis is a common chronic relapsing skin disease characterized by erythematosquamous inflammatory rashes in areas with a high concentration of sebaceous glands. Despite the fact that the etiopathogenetic mechanisms of the development of seborrheic dermatitis remain not fully understood, at the present stage the leading role in the development of this disease is played by: changes in the quantity and qualitative composition of sebum, dysbiosis of the skin microbiome (in particular, overgrowth of Malassezia spp.), dysfunction of the epidermal barrier and an altered immune response. Trigger factors for the development and possible recurrence of seborrheic dermatitis include environmental factors, genetic predisposition, neurological diseases, musculoskeletal pathology, diabetes, hypertension, metabolic syndrome, depressive disorders, emotional stress and HIV infection.

Objective. To identify the relevant etiopathogenetic factors in the development of seborrheic dermatitis, associated and triggering conditions, and to review current therapeutic options for treating patients.

Materials and methods. A retrospective literature review was conducted in the PubMed, Elibrary, Elsevier, Google Scholar, and National Library of Medicine databases for the past 15 years – from 2010 to 2025—using the keywords «seborrheic dermatitis,» «treatment options for seborrheic dermatitis,» «risk factors,» «immunology,» «immunogenetics,» and «neurological disorders in patients with seborrheic dermatitis.»

Results. 54 publications were included in the review. Predisposing factors for the development of seborrheic dermatitis include male gender, genetic predisposition, immune system pathology, environmental factors, changes in the composition of the skin microbiome, and hormonal imbalances.

Conclusions. When treating seborrheic dermatitis, it is important not only to eliminate the symptoms of the dermatosis, but also to competently address all links in the pathogenesis. Today, studying the common links in the pathophysiology of seborrheic dermatitis and associated diseases is relevant and important, as influencing these mechanisms may be key to achieving long-term remission and improving patients’ quality of life.

Introduction. Systemic and topical retinoids are the gold standard for treating acne of varying severity. However, their use is often limited by dose-dependent side effects, the most prominent of which are xerosis, irritation, and disruption of the skin barrier function. These phenomena worsen patients’ quality of life and reduce treatment compliance. The use of specialized non-comedogenic moisturizers aimed at restoring the hydrolipidic mantle is considered a key component of adjuvant therapy to improve the tolerability of retinoid treatment.

Objective. To comprehensively evaluate the clinical efficacy, impact on objective skin parameters, quality of life, and organoleptic properties of ZINOVIT® Day Moisturizing Cream for Combination, Oily, Problem Skin with SPF 20 and ZINOVIT® Moisturizing Cream for Combination, Oily, Problem Skin in patients with acne during retinoid therapy.

Materials and methods. An open, comparative prospective study was conducted. The study included 40 patients aged 18 to 45 years with a diagnosis of acne and receiving retinoid therapy. Depending on the severity of acne and the type of therapy, the patients were divided into two groups. Group 1 (n=20): patients with severe acne receiving systemic isotretinoin at a dose of 0.5 mg/kg/day. Group 2 (n=20): patients with mild to moderate acne receiving topical retinoids (adapalene, adapalene+benzoyl peroxide, trifaraten). All patients were prescribed the study creams and cleansing for 8 weeks as adjuvant therapy.

Results. Statistically significant positive dynamics of DIA was noted in both groups. In Group 1, the median DIA decreased from 12.00 [11.25; 13.75] to 8.00 [5.25; 9.00] points by the 8th week (p<0.001). In Group 2, the median DIA decreased from 5.50 [4.25; 6.75] to 1.00 [1.00; 2.00] points (p<0.001). Skin hydration indices improved significantly: in Group 1 from 28.00 [19.00; 32.75] to 36.00 [35.00; 38.00] conventional units (p<0.001), in Group 2 from 29.50 [25.25; 35.00] to 35.50 [32.5; 38.00] conventional units (p=0.008). The TEWL value significantly decreased, indicating strengthening of the barrier function: in Group 1 from 14.00 [11.00; 17.75] to 8.50 [7.25; 10.75] g/m²/h (p<0.001), group 2 from 16.00 [13.25; 17.75] to 8.50 [7.25; 10.00] г/м²/ч (p<0.001). A significant decrease in skin oiliness and improvement in pore size were also recorded. The DIQI values demonstrated significant improvement in both. The organoleptic properties of the products received high marks (>70 % of “excellent” and “good” ratings). The moisturizing effect lasted up to 12 hours after application. There were no cases of study withdrawal due to severe xerosis caused by retinoid therapy.

Conclusion. The study results demonstrate that moisturizing products of the ZINOVIT® line are an effective and well-tolerated component of adjuvant therapy in patients with acne receiving retinoid treatment. Their use statistically significantly improves objective skin parameters (hydration, TEWL, oiliness, pore size and condition), reduces the severity of induced xerosis, improves quality of life, and increases patient compliance with primary therapy. The high organoleptic properties of these products ensure ease of daily use.

Background. Current demographic data demonstrate a steady increase in life expectancy, resulting in an increasing proportion of age-related conditions in the pattern of medical care seeking. In women over 45, conditions associated with the perimenopausal period occupy a particularly prominent place in the morbidity structure. Loss of peripheral vascular control, which occurs due to estrogen deficiency, leads to dilation of dermal and subcutaneous blood vessels, which can significantly worsen the course of rosacea. The use of menopausal hormone therapy (MHT) and TECAR therapy in perimenopausal patients appears to be a promising method for treating and maintaining stable remission in the erythematotelangiectatic subtype of rosacea.

Study objective. To comparatively evaluate the efficacy of TECAR therapy and MHT in perimenopausal patients with erythematotelangiectatic rosacea (ETR) in terms of clinical symptoms of the dermatosis and quality of life, taking into account short-term and long-term follow-up results.

Methods. A single-center, open-label, prospective, comparative, randomized study included 63 perimenopausal patients with ETR. MHT was administered as prescribed by a gynecologist using a continuous therapy preparation containing 1 mg estradiol and 10 mg dydrogesterone. TECAR therapy procedures were performed using the INDIBA Elite NS device. The modified dermatological index of the rosacea symptom scale (DIRSS) was used to evaluate the clinical efficacy of treatment. The impact of treatment regimens on the quality of life of patients with rosacea was determined using the dermatological index of quality of life (DIQL).

Results. Upon completion of treatment, significant positive dynamics were noted in all groups, reflecting the effectiveness of the methods used (p T1- T2<0.001 in all groups). However, the lowest DIQL values were observed in Group C, which received combination therapy using MHT and TECAR therapy. The dynamics of the DIQL indicator correlated with the clinical effectiveness of the therapeutic regimens: the most pronounced positive effect on the quality of life of patients with ETPR was provided by the combination of MHT and TECAR therapy in both the short-term and long-term follow-up periods.

Conclusion. Combination treatment of ETPR using MHT and TECAR therapy is superior in effectiveness to monotherapy with the components of the method, which is associated with the synergism of MHT and radiofrequency therapy in relation to the vascular component of the dermatosis, as well as the anti-inflammatory effects of TECAR therapy.

Objective. To develop and evaluate the effectiveness of a comprehensive approach to correcting blood cytokine levels in patients with psoriatic arthritis (PsA) associated with metabolic syndrome (Ms), including tofacitinib (Tofa) and physiotherapy.

Material and methods. The study included 230 patients with PsA and Ms, randomized into 5 groups. All patients received standard drug therapy (SDT) for Ps A. Group 1 received St alone, group 2 received an additional 30 sessions of intravenous laser irradiation (SVLI+St), group 3 received an additional 30 sessions of 311 nm phototherapy (Ft+St), Group 4 received tofacitinib 10 mg 2 times a day for 6 months (Tofa+St), and group 5 received a combination of SVLI+Ft+Tofa+St. Blood levels of interleukins (IL) – 1β, -2, -4, -6, -8, -10, -13, -17, -18, -23, TNF-α, and INF-γ were determined using enzyme-linked immunosorbent assay.

Results. St therapy had no effect on the imbalance in the pro- and anti-inflammatory cytokine system in the blood. The greatest corrective effect was noted in the SVLI+Ft+Tofa+St group, where there was a decrease in the blood IL-1β by 72,2%, IL-2 by 67%, IL-6 by 79,5%, IL-8 by 80,6%, IL-13 by 51,2%, IL-17 by 64,7%, IL-18 by 40,1% IL-23 by 55,9%, TNF-α by 77,4%, INF-γ by 61,2% and an increase in the levels of IL-4 by 73,2%, IL-10 by 123,5%.

Conclusion. A comprehensive treatment program with the additional use of SVLI, Ft, and Tofa effectively corrected the cytokine status of the blood of patients with PsA and MS, resulting in a 40,1 %–80,6% reduction in baseline proinflammatory cytokine levels and an increase in antiinflammatory IL-4 and IL-10 levels by 73,2% and 123,5%, respectively.

Acne is a multifactorial disease that develops as a result of the interaction of numerous etiologic factors. The key pathophysiological factors of the disease are well understood; however, dermatovenerologists often note that acne patients are resistant to traditional therapy, which may be due to comorbid conditions and medications. This article presents a systematic review of the most common comorbidities, which determine the range of diagnostic tests and therapeutic options for the combined course of acne.

Retinoid dermatitis is a predictable, dose-dependent irritant inflammatory skin reaction that occurs predominantly during the early phase of retinoid therapy and may significantly reduce patient adherence. The increasing frequency of retinoid use and the expansion of indications in both dermatology and cosmetic practice underscore the need for unified approaches to the prevention, diagnosis, and management of retinoid-induced dermatitis. This review systematizes current data on the pathogenesis of retinoid dermatitis, with particular emphasis on RAR/RXRmediated transcriptional reprogramming, epidermal barrier dysfunction accompanied by increased transepidermal water loss (TEWL), inflammatory chemokine activation, and neurosensory sensitization involving transient receptor potential (TRP) channels. The phenomenon of retinization is discussed separately as a physiological adaptive phase of the cutaneous response to retinoid exposure. A clinical and practice-oriented concept is proposed linking the chemical structure of retinoids, receptor selectivity, and tolerability profiles. Risk factors for retinoid dermatitis, approaches to differential diagnosis with allergic contact dermatitis and rosacea, as well as prevention and severity-stratified management algorithms are presented, with a focus on maintaining therapeutic efficacy while minimizing adverse effects.

Palmoplantar psoriasis is a socially significant form of chronic dermatosis leading to a marked decrease in the quality of life and limitation of work activity. The search for effective and safe treatment methods, especially in the presence of contraindications to systemic therapy, remains relevant.

Objective. To evaluate the clinical efficacy and tolerability of pulsed dye laser in patients with palmoplantar psoriasis.

Material and methods. Two clinical cases are described. The first patient (61 years old) received a combination of topical therapy (salicylic acid, betamethasone) and a course of pulsed dye laser. The second case (a patient with controlled type 2 diabetes mellitus and intolerance to methotrexate) was treated with pulsed dye laser after discontinuation of the cytostatic agent. Efficacy was assessed by the dynamics of the palmoplantar psoriasis severity index (PPASI).

Results. Both patients showed significant positive dynamics. In the first case, the PPASI score decreased from 18 points to 1 point. In the second case, it decreased from 15 points to 0.5 points. There were no side effects from phototherapy.

Conclusion. Pulsed dye laser demonstrated high efficacy and good tolerability in the treatment of palmoplantar psoriasis. This method can be considered an optimal treatment option, especially in the presence of comorbid conditions that limit the use of systemic medications.

Psoriasis has a significant negative impact on patients’ quality of life, including social stigma, and is associated with various comorbidities, including psychosocial problems. Despite numerous scientific studies, various patient management approaches, and the availability of modern medications, a number of problems and challenges remain for the medical community, including the stratification of patient categories that present challenges. This article presents the results of a Russian expert consensus on defining and managing the definitions of «Difficult to Manage» and «Hard to Treat» patients with psoriasis.

On December 18, 2025, an expert consultation on «Practical Aspects and Prospects for the Use of the Emollient LIPIKAR BAUME AP+MAX®» was held in Moscow. This scientific event provided a platform for discussing the skin microbiome and its role in the pathogenesis of chronic skin diseases, particularly atopic dermatitis, taking into account current scientific data. The consultation also addressed the use of the new emollient+ LIPIKAR BAUME AP+MAX® in patient management algorithms for atopic dermatitis, based on current clinical protocols. The discussion focused on the mechanisms of itching in atopic dermatitis, as well as the relationship between xerosis and itching in light of the prospects for the use of emollients+. Data on the effectiveness of the new emollient+ LIPIKAR BAUME AP+MAX® in patients with atopic dermatitis were also discussed.

On December 18, 2025, an in-person expert council meeting was held in Moscow on the topic: «Practical Issues of рhotobiomodulation and рhotodynamic Therapy in Dermatology and Cosmetology.» This scientific event served as a platform for discussing accumulated clinical and organizational issues in the application of phototechnologies whose mechanism of action is based on photobiomodulation effects or photodynamic reactions, taking into account the practical experience of experts and scientific data. The expert council also discussed the development of recommendations for the use of these technologies, depending on their mechanism of action. The topic of discussion was the prospects for the application of photobiomodulation and photodynamic therapy in dermatology and cosmetology. The issues put to a vote were discussed, and consensus was reached on all positions. The culmination of the two expert council sessions was the development of recommendations on the application of these technologies.

Collagen is the main structural protein of connective tissue, determining the biomechanical properties and integrity of the skin. This paper presents an analysis of current data on the physiological role of collagen in the dermis and describes the molecular mechanisms of chronological and photoaging. Particular attention is paid to the role of matrix metalloproteinases (MMPs) in the process of collagen scaffold fragmentation. Current data on the effectiveness of oral hydrolyzed collagen for maintaining healthy skin and other connective tissues are reviewed. Particular attention is paid to analyzing the feasibility of using complex supplements containing collagen types I, II, and III. A critical review of the absorption mechanisms and action of bioactive peptides, clinical trial data, and meta-analyses is provided, and common myths associated with the separate use of different types of collagen are addressed.

As research in longevity medicine rapidly develops, biological age is increasingly viewed as the most promising integrated indicator combining biomarker signatures and possessing clinical significance. This paper describes the development of an artificial intelligence system for estimating biological age based on multimodal biomedical data. Eight categories of biomarkers were analyzed: bioimpedance analysis, complete blood count and biochemistry, coagulation profile, lipid profile, endocrine status, inflammatory markers, and prostate-specific antigen. Deep neural network architectures (MLP, DANet, FT-Transformer, GANDALF) and explainable AI methods (SHAP) were applied to achieve a more accurate interpretation. The aggregated model, using multiple categories of indicators, achieved a mean absolute error of 6.7 years and a Pearson correlation coefficient of 0,83 with chronological age. The system enables the interpretation of the contribution of individual biomarkers to agerelated acceleration and patient risk stratification, opening up opportunities for personalized medicine and preventive strategies. The results have been validated in the Russian population.

Modern aesthetic facial surgery strives for comprehensive restoration of both tissue position and lost volume during the correction of involutional changes. Composite SMAS lifting (Deep Plane technique) ensures reliable repositioning of sagging deep structures, while structural lipofilling corrects age-related atrophy of fat compartments. Performing these procedures in a single operation represents a synergistic approach aimed at achieving the most natural and long-lasting rejuvenation results. This article describes in detail the surgical stages and technical nuances of the combined technique, including harvesting, processing according to the Coleman protocol, and injection of autologous fat after a deep plane lift. Particular attention is paid to safety, graft integration, and the advantages of a single-stage procedure.

The problem of patient recovery after injuries and diseases of the musculoskeletal system in a military sanatorium by using classes on mechanotherapy devices as part of complex rehabilitation therapy is currently relevant. A study was conducted in Russian military medical organizations on the use of mechanotherapy along with physical therapy and physiotherapy on ARTROMOT and KINETEC devices; the Exarta kinesiotherapy unit; ORMED-kineso devices and the HUBER biofeedback device. The research results at the Volga Clinical Sanatorium and Pyatigorsk Sanatorium confirm that an integrated approach to rehabilitation, including both traditional methods and modern biofeedback technologies, can significantly improve the effectiveness of treatment and restore the patient’s functional capabilities.